








### NTC story

- NTC is an R&D-driven pharmaceutical company headquartered in Milan, Italy.
- NTC stands for Novelty and Technology to best take Care
  of our customers, partners, patients and of our employees.
- We act globally and we sell in almost 100 countries to approximately 250 partners, under a B2B commercial model. Our product portfolio is broad, mostly in Ophthalmology but diversified in Gynecology, Gastroenterology and Pediatrics too.
- We undertake direct commercial activities in Italy and Spain, entirely focused on Ophthalmology.
- NTC is controlled by an Italian private equity fund with a strong reputation, Wise SGR.





# Novelty and Technology for Care


Our range of products attests to our historical vocation for innovation aimed at improving the experience of patients and healthcare practices.

Novelty: we focus on R&D in Ophthalmology.
 Our clinical development program in Eye Health is among Europe's largest ones over the past 10 years, involving several thousands patients in controlled clinical trials.

We have diversified our R&D efforts also in Gynecology, Gastroenterology and Pediatrics.

- Technology is a key element in our strategy.
   Working in partnership with qualified CMOs/CDMOs, primarily in the EU, allows us to leverage many different technologies.
- We Care about patients and customers and we constantly measure clients satisfaction.






#### Therapeutic Gestures

Our scientific research and technology drive our efforts to an innovation aimed at discovering specific therapeutic gestures: simple and intuitive, sustainable, and technically advanced for empowering the patient.

- Simplification gestures that reduce the frequency and duration of therapy, facilitate taking medications.
- and the second
- Sustainable gestures
   that leads to more ethical
   consumption and the
   adoption of a healthcare
   praxis that prevents the
   overuse of drugs.



- **Balance** gestures
  that lead to new perceptual
  experiences, improving
  the immediate well-being
  effects of the treatment
  and allowing conditions of
  harmony and health to be
  maintained over time.
- Technological gestures modify the administration of the product through intelligent and innovative solutions, reducing the burden of the repetitiveness.





# Innovation to become a partner of choice

- Given a growing awareness of global antibiotic resistance, our vision is focused on developing better documented antibiotics for a more correct use, and innovative antiseptics.
- In NTC, innovation seats on an undisputed larger proposal. In **Ophthalmology** we offer different antibiotics and antiseptic products. In addition, our core focus are therapeutic solutions for ocular surface, with a broad portfolio of dry-eye and anti-inflammatory products.
- We have diversified pipeline covering three different areas:
   Gynecology with an innovative family of antibacterial product, Gastroenterology with innovative formulations promoting gastro-intestinal well-being and transit and Pediatrics with easy to take, child-tailored products.
- Moreover, we aim to develop drugs at affordable prices.





### Values & Responsabilities

- We respect and value processes and methodologies:
   Our management has a vast experience and strong success stories in large multinationals.
- Diversity is embedded in our story.
   We are involved in sustaining local communities, promoting diversity and respecting our employees.
- We want to operate and assure access to Health Care and to have an impact on human rights and society.
- We are aware of the importance of Product Quality and Safety because we care about our patients and customers, and we want to monitor each stage of the manufacturing value chain.
- We intend to protect the environment minimizing waste generation and setting processes and practices for the conservation of natural resources, water and energy.





# Creating Shareholders value

- We have generated double digit growth both top and bottom line for five consecutive years, and we plan to further accelerate in the coming few years.
- We are investing significantly, with a mix of resources: equity, debt and self financing.
- Our Financial Stetements is audited by E&Y since 2016.
- We are compliant with the Legislative Decree 231/2001 and the General Data Protection Regulation 196/2003 (GDPR).
- We are certified ISO 13485 and MDSAP in Canada and Brazil.
  - We audit our suppliers and partners to ensure quality alignment (GMP/GCP/ICH guidelines).





### Where you can find more about us

www.ntcpharma.com
www.ntcespana.es
LinkedIn
Congresses: CPHL ESCRS SIAIR SOL

Congresses: CPHI, ESCRS, SIAIP, SOI, SEO

#### NTC operations and headquarters:

Via dei Gracchi 35, 20146 Milan (Italy)

#### Our legal site:

Via Razza 3, 20124 Milan (Italy)

#### NTC Italy Ophthalmic unit:

Via dei Gracchi 35, 20146 Milan (Italy)

#### **NTC Spain Ophthalmic unit:**

C/ Alcalá 96, 2° centro, 28009 Madrid (Spain)





#### Ntc S.r.l. Con Socio Unico

Sede operativa: Via dei Gracchi, 35 20146 Milano

Sede Legale: Via Luigi Razza, 3 20124 Milano Tel. +39 02 438 504 1 Fax +39 02 481 953 01

This document is distributed for informational purposes only. Unauthorized use, disclosure or reproduction is prohibited.

Revised: September 2021



